Change of number of shares and votes in Xbrane

31 October 2022 - 08:00

Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed share issue of in total 2,361,112 shares. The share issue has resulted in a change of the registered share capital and shares and votes in Xbrane.

As of 31 October 2022, the total number of shares and votes in the Company amounts to 27,506,018. The Company's registered share capital amounts to approximately SEK 6,166,466.

Provided by: MFN
Nasdaq First North GM Stockholm (Sweden)
Xbrane Biopharma AB
Xbrane Biopharma develops and manufactures biosimilars and generic long-acting injectables. It offers products including Spherotide, for the treatment of prostate cancer, breast cancer, endometriosis, and myoma and Xlucane, a ranibizumab biosimilar for the treatment of age-related macular degeneration, diabetes-related macular edema, diabetic retinopathy, and retinal vein occlusion....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More